Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Oncolytic viruses are engineered to replicate within tumor cells, leading to cell lysis and the release of tumor antigens.
• Checkpoint inhibitors have shown promise but are not universally effective, necessitating combination strategies.
• Adenoviruses are extensively studied for oncolytic virotherapy due to their safety profile and genetic manipulability.

Purpose of the Study:

• To review adenoviruses as a class of oncolytic viruses for cancer therapy.
• To discuss the potential of adenoviruses, alone and in combination with checkpoint inhibitors, to convert "cold" tumors to "hot" tumors.
• To propose a combination therapy strategy based on the cancer-immunity cycle.

Main Methods:

• Review of clinical trial data and scientific literature on oncolytic adenoviruses.
• Analysis of adenovirus design features relevant to therapeutic efficacy.
• Exploration of synergistic mechanisms between adenoviruses and checkpoint inhibitors.

Main Results:

• Adenoviruses demonstrate potential in stimulating anti-tumor immune responses.
• Combination therapy with checkpoint inhibitors may enhance efficacy in non-responsive tumors.
• The cancer-immunity cycle provides a framework for optimizing combination treatment strategies.

Conclusions:

• Adenoviruses hold significant promise as oncolytic agents, particularly in combination therapies.
• Strategic combinations can overcome tumor resistance and improve patient outcomes.
• Further research into "mix-and-match" approaches is warranted to maximize therapeutic benefit.